急性缺血性卒中早期继续或中断抗凝治疗
该研究为PASS试验的事后分析,纳入入院时正在使用抗凝药的急性缺血性卒中患者,比较继续与中断抗凝的临床结局。中断抗凝组血栓事件更多、死亡率和不良结局更差,但校正混杂因素后差异无统计学意义;继续抗凝组未发生大出血。
要点
- 入院时使用抗凝药的急性缺血性卒中患者占9%(192/2101),其中186例使用维生素K拮抗剂。
- 中断抗凝组血栓事件11% vs 继续组3%(P=0.038),但校正混杂因素后无统计学显著差异。
- 继续抗凝组未发生大出血事件。
核心结论
- 本研究中临床医生倾向于继续抗凝治疗;中断抗凝与血栓事件风险增加和临床结局更差相关,但校正潜在混杂因素后组间无统计学显著差异;继续抗凝组大出血风险未增加。
研究设计与样本
- PASS(Preventive Antibiotics in Stroke Study)试验的事后分析,纳入入院时使用抗凝药的急性缺血性卒中患者192例(占全部2101例的9%),其中186例使用维生素K拮抗剂。
主要发现
- 中断抗凝组35/192例(18%),其美国国立卫生研究院卒中量表评分中位数高于继续抗凝组(13 vs 4,P<0.001)。
- 中断抗凝组血栓事件发生率11% vs 继续抗凝组3%(P=0.038)。
- 两组均未发生大出血事件。
- 中断抗凝组90天死亡率31% vs 继续抗凝组15%(P=0.019),改良Rankin量表评分0-2分者20% vs 55%(P<0.001)。
- 校正潜在混杂因素后,组间差异均无统计学意义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: There is no consensus on whether anticoagulation should be continued or temporarily stopped in patients suffering acute ischemic stroke while using anticoagulation. We assessed treatment variations and outcomes in these patients. METHODS: Post hoc analysis of PASS (Preventive Antibiotics in Stroke Study). We included patients with acute ischemic stroke who used anticoagulation at admission. We compared clinical outcomes, thrombotic, and major bleeding events at 3 months. RESULTS: Nine percent (192/2101) of the patients with acute ischemic stroke used anticoagulation at admission (186 vitamin K antagonists). Anticoagulation was discontinued in 35/192 (18%) patients. These patients had higher National Institutes of Health Stroke Scale scores than patients in whom anticoagulation was continued (median, 13 versus 4; P<0.001). Thrombotic events occurred more frequently in patients in whom anticoagulation was discontinued (11% versus 3%; P=0.038). There were no major bleeding events in either group. Mortality and clinical outcomes at 90 days were worse in patients in whom anticoagulation was discontinued (mortality, 31% versus 15%; P=0.019 and modified Rankin Scale score of 0-2, 20% versus 55%; P<0.001). After adjustment for potential confounders, there were no statistically significant differences between groups. CONCLUSIONS: In our study, clinicians tended to continue anticoagulation in patients with acute ischemic stroke. Discontinuation was associated with an increased risk of thrombotic events and worse clinical outcome. Risk of major bleeding was not increased in patients in whom anticoagulation was continued. CLINICAL TRIAL REGISTRATION: URL: https://www.controlled-trials.com. Unique identifier: ISRCTN66140176.
引用
- Groot AE, Vermeij JM, Westendorp WF, et al. Continuation or Discontinuation of Anticoagulation in the Early Phase After Acute Ischemic Stroke. Stroke. 2018. PMID: 29844030. doi:10.1161/STROKEAHA.118.021514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。